Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 4/20 | 0.35 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610642 | 0.86 | CTSD (0.42) | MMP1MMP2MMP3RENPSEN1 | |
| SCHEMBL6849973 | 0.77 | REN (0.38) | MMP1MMP2MMP3RENCPB2 | |
| SCHEMBL29429781 | 0.70 | CPB2 (0.49) | RENCPB2F2RL1 | |
| SCHEMBL30451392 | 0.69 | CPB2 (0.60) | CPB2 | |
| SCHEMBL30451831 | 0.68 | CPB2 (0.61) | CPB2 | |
| SCHEMBL29429780 | 0.68 | CPB2 (0.71) | CPB2 | |
| SCHEMBL30657894 | 0.67 | CPB2 (0.57) | CPB2 | |
| SCHEMBL6850689 | 0.66 | PSEN1 (0.46) | MMP1MMP2MMP3RENF2RL1 | |
| SCHEMBL7349316 | 0.66 | REN (0.66) | REN | |
| SCHEMBL7349332 | 0.66 | REN (0.66) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | claimed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | MMP1 850/4885MMP2 788/4885MMP3 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.